Feds License Protein That Skips Chemo for Stem Cell Transplants
Published Date: 9/23/2026
Notice
Summary
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Safer stem-cell transplant conditioning
The NIH is offering patent rights for a preclinical therapy (DT390-biscFV(cMPL)) that can be used as a new conditioning regimen to make hematopoietic stem and progenitor cell (HSPC) transplants safer, especially for leukemia patients and older people who cannot tolerate chemo or radiation. The notice says the technology limits chemotherapeutic cytotoxicity, better penetrates bone marrow, has a short half-life, and has in vivo (animal) data available.
Licensing and collaboration chance for developers
The government is making patent rights available for licensing and commercial development for the DT390-biscFV(cMPL) technology (HHS Ref. No.: E-188-2021-0) and is seeking statements of capability or interest for collaborative research to further develop, evaluate, or commercialize it. Licensing contact and a collaborative research contact are provided so companies and research groups can begin discussions now; a signed Confidential Disclosure Agreement may be required to get unpublished information.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20705, Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.
2026-20424, National Cancer Institute; Notice of Meeting
The President's Cancer Panel is holding a free virtual meeting on October 15, 2026, to talk about how GLP-1 medications can help lower cancer risks linked to obesity. Anyone interested can join online or send in comments beforehand. This meeting is a great chance for patients, doctors, and researchers to learn about new ways to fight cancer and improve health.
2026-20365, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings on October 29-30, 2026, to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like biochemistry, software engineering, and mental health will be affected, with no direct money changes announced but important decisions coming soon.
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
Previous / Next Documents
Previous: 2026-19427, Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of Previously Approved Collection; Petition for Commutation of Sentence
The Department of Justice’s Office of the Pardon Attorney is updating its form for people asking to shorten their prison sentences. They want your feedback on how easy the form is to use and how much time it takes to fill out. Comments are open for 30 days, and this update aims to make the process smoother and less time-consuming for everyone involved.
Next: 2026-19432, Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Title-Procurement Quota Certification and Recordkeeping Requirements
The DEA wants to keep collecting info from people who handle certain controlled substances to make sure they follow rules about how much they can get and keep. They’re asking for your thoughts on this paperwork for the next 60 days, until November 23, 2026. This won’t cost extra money but helps keep things clear and fair for everyone involved.